reason report
tax benefit rear view mirror focu shift back
bottom line updat mp model reflect
earn well manag guidanc
signific chang model improv pfe tax
rate project forward
management believ new adjust tax rate sustain balanc
net effect chang increas ep sale
respect call laid
capit alloc object includ repatri
major cash equival share
repurchas comment call suggest like remain
lead edg futur consolid within larg cap pharma
maintain mp rate dcf-base pt driven
primarili lower tax rate
like qtr pfe innov busi grew y/i
includ eliqui allianc direct sale revenu growth y/i
eliqui number one new-to-brand oral anticoagul
prescrib cardiologist differ market xeljanz grew y/
next leg growth kick recent us approv
psoriat arthriti potenti approv ulcer coliti june
year management highlight jak kinas program seven on-going
studi includ phase jak select inhibitor
atop dermat well two phase program alopecia areata
aa us highlight potenti market opportun see
didnt like qtr ibranc intern revenu
disappoint post loss due one-tim price
adjust revenu management view ibranc updat
posit futur patient access ibranc europ note
sequenti growth ibranc patient patient treat
make materi chang ibranc estim oper
margin quarter bp estim
non-gaap tax rate drove beat made
minor tweak cog opex assumpt pfe expens
guidanc rel line expect
dcf discount
rate termin growth rate
net debt total capit
price-to-earnings lt ep growth
estimate lt ep growth compound-annual-growth-rate
compani inform leerink partner llc research
revenu
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rate market perform current valuat ep estim
ep estim see littl downsid risk share near
term believ manag enhanc disclosur two busi unit innov health
global essenti health simultan highlight tail valu establish product
reveal drive forc behind fail bid azn mp need addit
scale pipelin asset within innov busi unit view target like
would still enhanc pfe abil success break larger combin compani
sustain entiti also significantli enhanc pfe long-term financi flexibl
figur except per share data
figur
figur
forecast sale forecast sale forecast forecast pfizer inc
trade low end leerink major pharmaceut univers azn gsk
nv nvo sni may appeal value-bas investor base high
oper cash flow yield dividend yield opportun organ
growth appear rel limit discount cash flow analysi valu
sale profit assum discount rate termin growth
risk valuat
risk invest thesi valuat includ exclus loss therapeut substitut
slow key driver trend large-scal put dividend risk product
commerci risk face in-class competit notabl fda breakthrough-
figur mm except per share data
sale
sale
sale
sale
sale
sale
sale
sale
sale
provis incom tax
net incom attribut minor interest
net incom attribut non-gaap
sale
non-gaap ep attribut dilut
total allianc revenu includ contribut aricept spiriva rebif macugen apixaban enbrel us canada
figur mm except per share data
gip
v/o
gep
figur mm except per share data
sale
sale
sale
sale
sale
sale
sale
sale
sale
provis incom tax
net incom attribut minor interest
net incom attribut non-gaap
sale
non-gaap ep attribut dilut
total allianc revenu includ contribut aricept spiriva rebif macugen apixaban enbrel us canada
